Literature DB >> 2979247

Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.

W C Orr1, M G Robinson, T J Humphries, J Antonello, A Cagliola.   

Abstract

The present study attempts to assess the alteration in patterns of gastro-oesophageal reflux as assessed by 24-h oesophageal pH monitoring by varying degrees of H2-receptor blockade with famotidine. Subjects were 12 patients with complaints of daily heartburn who demonstrated at least 6% of acid mucosal contact time by 24-h ambulatory oesophageal pH monitoring. All subjects had a positive Bernstein test, and nine of the 12 subjects had erosive oesophagitis. The study was conducted as a double-blind crossover design utilizing 40 mg nocte, 20 mg b.d., and 40 mg b.d. and placebo treatments. Results indicated that all treatments significantly reduced the 24-h percentage acid contact time (P less than 0.05) compared to placebo. The two b.d. treatment regimens also significantly (P less than 0.05) reduced the number of episodes lasting longer than 5 min. Only the b.d. regimens successfully lowered the percentage of upright acid exposure. All treatments significantly (P less than 0.01) reduced the percentage of supine acid contact time, as well as the number of episodes lasting more than 5 min. It is concluded that gastro-oesophageal reflux disease may well require a b.d. dosing regimen with famotidine in order to achieve optimal mucosal healing and day time symptom control.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2979247     DOI: 10.1111/j.1365-2036.1988.tb00692.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Treatment of gastro-oesophageal reflux disease in adults.

Authors:  J P Galmiche; E Letessier; C Scarpignato
Journal:  BMJ       Date:  1998-06-06

Review 2.  Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  H D Langtry; S M Grant; K L Goa
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

3.  Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis.

Authors:  I C Wesdorp; W Dekker; H P Festen
Journal:  Dig Dis Sci       Date:  1993-12       Impact factor: 3.199

Review 4.  Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.

Authors:  J G Hatlebakk; A Berstad
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

5.  Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.

Authors:  J M Marrero; J S de Caestecker; J D Maxwell
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

Review 6.  Medical treatment of esophageal motility disorders.

Authors:  H D Allescher; W J Ravich
Journal:  Dysphagia       Date:  1993       Impact factor: 3.438

7.  Basal acid output and gastric acid hypersecretion in gastroesophageal reflux disease. Correlation with ranitidine therapy.

Authors:  M J Collen; D A Johnson; M J Sheridan
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

Review 8.  Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

Authors:  N J Bell; R H Hunt
Journal:  Gut       Date:  1992-01       Impact factor: 23.059

9.  Pharmacokinetics and pharmacodynamics of famotidine in patients with reflux oesophagitis.

Authors:  U Gladziwa; S Wagner; K V Dakshinamurty; E el Desoky; B Dreuw; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.